Clinical trials: HEPATITIS C (HCV)
Cirrhosis, Chronic Hepatitis C
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy…
- Trial name
- NCT00502086
- Testing
- Viusid (nutritional supplement)
- Where
- Cuba
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
HEPATITIS C (HCV), Opioid Use Disorder
Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs
This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject…
- Conditions
- HEPATITIS C (HCV), Opioid Use Disorder, Substance Use Disorder (SUD), Drug Use Disorders
- Trial name
- NCT07631559
- Testing
- Partner navigation intervention booster session
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
HEPATITIS C (HCV), Incarceration
Implementing Low-Barrier HCV Treatment in a Jail Setting
The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily.
- Conditions
- HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
- Trial name
- MINMON-J (NCT06953479)
- Testing
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Lifespan
Hepatitis C, Chronic
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
The objective was to investigate the antiviral effect, safety, and pharmacokinetics of BI 201335 (Faldaprevir), given as a soft gelatine capsule, in patients with hepatitis C virus (HCV) genotype 1 infection.
- Trial name
- NCT00774397
- Testing
- BI 201335 NA 240 mg QD / LI, PegIFN/RBV, BI 201335 NA 120mg QD / LI
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 719 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis c Genotype 1
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.
- Trial name
- NCT04246723
- Testing
- Narlaprevir, Ritonavir, Sofosbuvir
- Where
- 5 sites in Russia
- Volunteers
- 85 people
- Sponsor
- R-Pharm
Hepatitis C
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.
- Trial name
- CBZF961X2201 (NCT01825980)
- Testing
- BZF961, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
HIV/AIDS, Hepatitis C
Study of HIV, HCV, APS and Phylogenetics for PWID
This study will determine whether assisted partner notification services (APS) can identify and link to care, the sexual and needle-sharing partners of HIV-infected and HIV/hepatitis C (HCV) co-infected persons who inject drugs…
- Trial name
- SHARP (NCT03447210)
- Testing
- Assisted Partner Services
- Where
- 3 sites in Kenya
- Volunteers
- 4,301 people
- Sponsor
- University of Washington
Hepatitis C, Hepatitis C, Chronic
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
A clinical observational study for patients with HIV co-infected with hepatitis C that investigates the levels of their health literacy, hepatitis C and HIV knowledge.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
- Trial name
- NCT03413696
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Hepatitis C Infection, HIV Infection
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
This study is aimed at assessing the safety of candidate Hepatitis C vaccines AdCh3NSmut/MVA-NSmut and HIV vaccines ChAdV63.HIVconsv/MVA.HIVconsv when administered separately or in combination to healthy volunteers.
- Trial name
- NCT02362217
- Testing
- AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Hepatitis C, Hepatitis C, Chronic
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection
- Trial name
- NCT04019717
- Testing
- AT-527, Daclatasvir
- Where
- 3 sites in Belgium, Mauritius and 1 more
- Volunteers
- 10 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis C
Community Access, Retention in Care, and Engagement for Hepatitis C Treatment
The main goals of the CARE-C study are to demonstrate the effectiveness of HCV models of care in a rural state (A) to overcome barriers to HCV treatment uptake, (B) to increase retention in care, and (C) to broaden access to…
- Trial name
- CARE-C (NCT03581383)
- Testing
- PREP-C, Modified ECHO, Patient Telemedicine Questionnaire
- Where
- United States
- Volunteers
- 657 people
- Sponsor
- Jens Rosenau
Hepatitis C, Chronic
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic…
- Trial name
- NCT02461745
- Testing
- ombitasvir, paritaprevir/r, dasabuvir + ribavirin, ombitasvir, paritaprevir/r, dasabuvir
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Kaiser Permanente
Hepatitis C
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in Asiatic patients with Hepatitis C chronic infection identified as non responders…
- Trial name
- ECLIPSE 3 (NCT01024894)
- Testing
- Interleukin-7
- Where
- 4 sites in Taiwan
- Volunteers
- 15 people
- Sponsor
- Cytheris SA
Hepatitis C
The DETECT HCV Screening Trial
The investigators propose to compare the effectiveness of nontargeted rapid opt-out hepatitis C (HCV) screening versus targeted rapid opt-out HCV screening using recommended risk characteristics in multiple urban emergency…
- Trial name
- DETECT HCV (NCT04003454)
- Testing
- HCV Screening
- Where
- 3 sites in United States
- Volunteers
- 147,533 people
- Sponsor
- Denver Health and Hospital Authority
Chronic Hepatitis C
Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania
This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), + dasabuvir (DSV), +/- ribavirin…
- Trial name
- NCT02807402
- Volunteers
- 522 people
- Sponsor
- AbbVie
Hepatitis C, Opioid Use Disorder
Rural New England Health Study (Phase 2)
This study will integrate mobile hepatitis C virus (HCV) testing and treatment with expanded syringe access in order to improve uptake of HCV testing and treatment, and reduce syringe sharing behavior in rural northern New…
- Conditions
- Hepatitis C, Opioid Use Disorder, IV Drug Usage
- Trial name
- DISCERNNE (NCT05466331)
- Testing
- Mobile Tele-HCV Care, Enhanced Usual Care
- Where
- 3 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Baystate Medical Center
Hepatitis C
Phase 3 Study of Sofosbuvir and Ribavirin
This study was to assess the safety and efficacy of sofosbuvir (GS-7977; PSI-7977) in combination with ribavirin (RBV) administered for 12 weeks compared with pegylated interferon (PEG)/RBV administered for 24 weeks in…
- Trial name
- FISSION (NCT01497366)
- Testing
- Sofosbuvir, PEG, RBV
- Where
- 97 sites in United States, Australia and 6 more
- Volunteers
- 527 people
- Sponsor
- Gilead Sciences
Hepatitis C
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.
- Trial name
- FOURward (NCT02175966)
- Testing
- DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
HCV Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) in participants with chronic genotype 1…
- Trial name
- NCT01987453
- Testing
- LDV/SOF, RBV
- Where
- 43 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Infection
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients
The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotypes 2 infection.
- Trial name
- NCT02482077
- Testing
- SOF+RBV, SOF+DCV, LDV/SOF
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Humanity and Health Research Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.